Valiant Laboratories Ltd
VALIANTLABValiant Laboratories Ltd
VALIANTLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -111.92 | 2.09 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Valiant Laboratories Limited specializes in manufacturing pharmaceutical intermediates, particularly paracetamol API.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 338.77 | 191.74 | 159.59 | |||
Raw Materials | 276.76 | 168.67 | 164.14 | |||
| Power & Fuel Cost | 7.37 | 8.33 | ||||
| Employee Cost | 4.61 | 4.31 | ||||
| Selling & Administrative Expenses | 3.73 | 2.69 | ||||
| Operating & Other expenses | 6.35 | 6.46 | ||||
EBITDA | 39.95 | 1.28 | -4.55 | |||
| Depreciation/Amortization | 1.56 | 1.97 | 2.03 | |||
| PBIT | 38.39 | -0.69 | -6.58 | |||
| Interest & Other Items | 0.25 | 0.08 | 0.11 | |||
| PBT | 38.14 | -0.77 | -6.69 | |||
| Taxes & Other Items | 9.14 | -1.09 | -2.26 | |||
| Net Income | 29.00 | 0.32 | -4.43 | |||
| EPS | 8.91 | 0.08 | -1.02 | |||
| DPS | 0.00 | 0.00 | 0.00 | |||
| Payout ratio | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Valiant Laboratories Ltd | 1,549.40 | 2.09 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare VALIANTLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.71%
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.89%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
VALIANTLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeValiant Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Net loss of Valiant Laboratories reported to Rs 0.51 crore in the quarter ended June 2024 as against net profit of Rs 4.27 crore during the previous quarter ended June 2023. Sales declined 63.28% to Rs 18.88 crore in the quarter ended June 2024 as against Rs 51.41 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales18.8851.41 -63 OPM %-12.617.43 - PBDT0.376.24 -94 PBT-0.165.78 PL NP-0.514.27 PL Powered by Capital Market - Live
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Valiant Laboratories announced that the 3rd Annual General Meeting (AGM) of the company will be held on 8 August 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant